Literature DB >> 29442147

[Urosepsis].

Mathias W Pletz1,2, Sebastian Weis1,2,3, Christina Forstner1,4, Florian Wagenlehner5.   

Abstract

Urosepsis is defined as a severe disease due to organ failure caused by a urinary tract infection. An empirical antibiotic therapy should be instigated within the first hour after diagnosis. Urine cultures and blood cultures should be performed before antibiotic treatment. Further diagnostics should be carried out at an early stage to enable an interventional focus control in the case of urinary tract obstruction or abscess formation, if necessary. Gram-negative pathogens are most frequently isolated. Extended spectrum beta-lactamase (ESBL) forming bacteria as a cause of urosepsis are increasing. Carbapenemase-forming Enterobacteriaceae, on the other hand, are still rare. The empirical treatment consists of a broad spectrum beta-lactam antibiotic. While piperacillin/tazobactam, carbapenems and the new cephalosporin/beta-lactamase inhibitor (BLI) combinations are given as monotherapy, cephalosporins should be combined with aminoglycosides (preferred) or fluoroquinolones. If a combination therapy is given, it should be de-escalated to a monotherapy after 48-72 h.

Entities:  

Keywords:  Antibiotic therapy; Sepsis; Staphylococcus aureus; Urinary tract infections; Urogenital system

Mesh:

Substances:

Year:  2018        PMID: 29442147     DOI: 10.1007/s00063-018-0406-1

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  33 in total

Review 1.  Urosepsis--Etiology, Diagnosis, and Treatment.

Authors:  Nici Markus Dreger; Stephan Degener; Parviz Ahmad-Nejad; Gabriele Wöbker; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2015-12-04       Impact factor: 5.594

2.  Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

Authors:  Florian M Wagenlehner; Obiamiwe Umeh; Judith Steenbergen; Guojun Yuan; Rabih O Darouiche
Journal:  Lancet       Date:  2015-04-27       Impact factor: 79.321

3.  Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

Authors:  Yehuda Carmeli; Jon Armstrong; Peter J Laud; Paul Newell; Greg Stone; Angela Wardman; Leanne B Gasink
Journal:  Lancet Infect Dis       Date:  2016-04-20       Impact factor: 25.071

Review 4.  Fever in the elderly.

Authors:  D C Norman
Journal:  Clin Infect Dis       Date:  2000-07-25       Impact factor: 9.079

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

6.  Systemic inflammatory response syndrome criteria in defining severe sepsis.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo
Journal:  N Engl J Med       Date:  2015-03-17       Impact factor: 91.245

7.  Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: a case-control study.

Authors:  Shingo Chihara; Kyle J Popovich; Robert A Weinstein; Bala Hota
Journal:  BMC Infect Dis       Date:  2010-07-29       Impact factor: 3.090

8.  Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013.

Authors:  Zafer Tandoğdu; Ricardo Bartoletti; Tomasso Cai; Mete Çek; Magnus Grabe; Ekaterina Kulchavenya; Bela Köves; Vandana Menon; Kurt Naber; Tamara Perepanova; Peter Tenke; Björn Wullt; Truls Erik Bjerklund Johansen; Florian Wagenlehner
Journal:  World J Urol       Date:  2015-12-11       Impact factor: 4.226

9.  Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Authors:  Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079

10.  Metabolic Adaptation Establishes Disease Tolerance to Sepsis.

Authors:  Sebastian Weis; Ana Rita Carlos; Maria Raquel Moita; Sumnima Singh; Birte Blankenhaus; Silvia Cardoso; Rasmus Larsen; Sofia Rebelo; Sascha Schäuble; Laura Del Barrio; Gilles Mithieux; Fabienne Rajas; Sandro Lindig; Michael Bauer; Miguel P Soares
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

View more
  2 in total

Review 1.  [Urosepsis-targeted diagnostics and effective therapy].

Authors:  Jennifer Kranz; Fabian Stangl; Christoph Kuppe; Florian Wagenlehner; Matthias Saar; Laila Schneidewind
Journal:  Urologie       Date:  2022-05-06

2.  Construction and Evaluation of a Sepsis Risk Prediction Model for Urinary Tract Infection.

Authors:  Luming Zhang; Feng Zhang; Fengshuo Xu; Zichen Wang; Yinlong Ren; Didi Han; Jun Lyu; Haiyan Yin
Journal:  Front Med (Lausanne)       Date:  2021-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.